120
Participants
Start Date
September 10, 2025
Primary Completion Date
October 14, 2025
Study Completion Date
December 6, 2025
A/Arkansas/08/2020 (pH1N1)
GMP-grade, cell-based influenza A (pH1N1) virus (Lot #24-005), derived via reverse genetics for use in controlled human infection studies.
Sham/Diluent (1X SPG+Arg+Gel)
Sterile diluent containing 1X Sucrose Phosphate Glutamate (SPG), 1% arginine, and 1% hydrolyzed gelatin, used as a sham comparator in the human challenge trial.
RECRUITING
Duke Vaccine and Trials Unit, Durham
RECRUITING
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore
National Institute of Allergy and Infectious Diseases (NIAID)
NIH